GlassScriptPhysician profile
Michaela Malko
NPI 1982273256
$6,649.03
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,245 · 2022: $2,785 · 2023: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $556 · Education: $62.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $555.98 |
| Education | $62.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $2,229.89 | 2021 | |
| Neuronetics, INC. | $1,117.90 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $641.42 | 2021-2023 | |
| Lundbeck LLC | $606.98 | 2022-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $394.50 | 2022-2023 | Rexulti |
| Abbvie INC. | $241.51 | 2022-2023 | |
| Amgen INC. | $167.26 | 2021-2022 | |
| Horizon Therapeutics Plc | $152.35 | 2021 | |
| Nevro Corp. | $141.40 | 2021 | |
| Idorsia Pharmaceuticals US INC | $140.50 | 2023 | Quviviq |
| Spr Therapeutics, INC | $114.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $106.80 | 2022-2023 | Invega Sustenna |
| Astrazeneca Pharmaceuticals LP | $93.89 | 2021-2022 | |
| Avanir Pharmaceuticals, INC. | $52.70 | 2022 | |
| Vanda Pharmaceuticals INC. | $52.52 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $43.87 | 2022 | |
| Lilly USA, LLC | $42.75 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $39.56 | 2022 | |
| Allergan, INC. | $37.97 | 2021 | |
| Indivior INC. | $35.48 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.82 | 2022-2023 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.71 | 2021-2022 | |
| Alkermes, INC. | $33.24 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.16 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $19.85 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.25 | 2021 | |
| Grt US Holding, INC. | $13.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Malko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.